Abbott Laboratories (ABT) Shares Rose While Diamond Hill Capital Management INC Decreased Its Stake

April 17, 2018 - By Sonya McDaniel

Abbott Laboratories (NYSE:ABT) Corporate LogoDuring Q4 2017 the big money sentiment increased to 0.91. That’s change of 0.04, from 2017Q3’s 0.87. 52 investors sold all, 558 reduced holdings as ABT ratio improved. 430 rose holdings while 123 funds bought holdings. Funds hold 1.22 billion shares thus 0.64% more from 2017Q3’s 1.21 billion shares. Pittenger And Anderson stated it has 67,317 shs. Greylin Investment Mangement Inc owns 46,381 shs for 0.57% of their capital. Advsrs Asset Incorporated holds 0.14% or 146,815 shs. Creative Planning invested 0.07% of its capital in Abbott Laboratories (NYSE:ABT). 6,100 were reported by Karpas Strategies Ltd. Gotham Asset Mngmt Ltd reported 0.71% in Abbott Laboratories (NYSE:ABT). Osborne Partners Mngmt Limited Company has invested 1.38% of its capital in Abbott Laboratories (NYSE:ABT). Fire Gp, Iowa-based fund reported 225,000 shs. Toth Advisory Corporation has 146,200 shs. 3.65M were reported by Mitsubishi Ufj Trust Banking Corporation. Ntv Asset Mgmt Ltd Limited Liability Company holds 0.72% of its capital in Abbott Laboratories (NYSE:ABT) for 45,164 shs. 7,629 are held by Palisades Hudson Asset Management Ltd Partnership. Everett Harris And Company Ca reported 1.64 million shs or 2.62% of all its holdings. Fort Point Cap Prtn Ltd reported 4,518 shs or 0.12% of all its holdings. Citizens & Northern Corp has invested 1.27% in Abbott Laboratories (NYSE:ABT).

ABT registered $28.95 million net activity with 1 insider purchase and 19 sales since October 23, 2017. Bracken Sharon J also sold $126,559 worth of Abbott Laboratories (NYSE:ABT) shs. On Friday, February 16 Fussell Stephen R sold $3.36M worth of Abbott Laboratories (NYSE:ABT). Another trade for 8,262 shs valued at $518,450 was made by BIRD ROGER on Friday, March 9. Another trade for 40,037 shs valued at $2.43M was made by STARKS DANIEL J on Tuesday, February 27. On Wednesday, February 28 $53,369 worth of stock was sold by Salvadori Daniel Gesua Sive. Blaser Brian J sold 27,733 shs worth $1.73 million.

According to 2017Q4 Securities and Exchange form the Ric Dillon decreased its holdings in Abbott Laboratories (ABT) by 4.35%. The company’s stock rose 5.88% while stock markets declined as Diamond Hill Capital Management Inc sold 480,031 shares. The hedge fund run by Ric Dillon is holding 10.56 million shares, compared to the 11.04M from the previous quarter. And the reported value of the major pharmaceuticals company is $602.64 million for the 2017Q4. Abbott Laboratories has $103.51 billion market cap. ABT reached $59.27 on during the last trading session after $0.78 change.Currently Abbott Laboratories is uptrending after 34.85% change in last April 17, 2017. ABT has 6.81M shares volume. The stock outperformed the S&P500 by 23.30%.

The Diamond Hill Capital Management Inc’s stake in Hanesbrands Inc. (NYSE:HBI) was increased by 840,169 shares to 10.06 million shares valued at $210.44 million in 2017Q4, according to the filing. It operates about $12.19B and $19.96B US Long portfolio. Diamond Hill Capital Management Inc has risen its stake in Microsoft Corp. (NASDAQ:MSFT) and also increased its holding in First Republic Bank (NYSE:FRC) by 999,122 shares in the quarter, for a total of 2.60 million shares.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on April, 18. They expect $0.58 EPS, up 20.83 % or $0.10 from last year’s $0.48 per share. ABT’s profit will be $1.01B for 25.55 P/E if the $0.58 EPS becomes a reality. After $0.74 actual EPS reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts -21.62 % negative EPS growth.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

In total 15 analysts cover Abbott Labs (NYSE:ABT). “Buy” rating has 13, “Sell” are 0, while 2 are “Hold”. 87% are bullish. 26 are the (NYSE:ABT)’s analyst reports since October 18, 2017 according to StockzIntelligence Inc. On Thursday, October 19 the firm has “Neutral” rating by Citigroup given. In Wednesday, January 24 report Stifel Nicolaus maintained it with “Buy” rating and $71.0 target. On Thursday, October 19 the stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given by RBC Capital Markets. On Monday, January 22 the rating was downgraded by BTIG Research to “Neutral”. On Thursday, January 25 the company was upgraded by William Blair. On Thursday, January 25 the stock of Abbott Laboratories (NYSE:ABT) earned “Overweight” rating by JP Morgan. In Wednesday, January 24 report BMO Capital Markets maintained it with “Buy” rating and $70.0 target. In Thursday, January 25 report Guggenheim maintained it with “Buy” rating and $72.0 target. On Thursday, October 19 the firm earned “Equal-Weight” rating by Morgan Stanley. On Tuesday, January 30 the stock has “Neutral” rating by Citigroup.

Abbott Laboratories (NYSE:ABT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.